EUVIMEDEUVIMED entdecken
Open Access

Effect of Burosumab on Muscle Function and Strength, and Rates of ATP Synthesis in Skeletal Muscle in Adults With XLH

Karl L Insogna iD, Rebecca Sullivan, Stephen Parziale iD, Yanhong Deng iD, Diana Carrano, Christine Simpson, Sylvie Dufour, Thomas Carpenter, Kitt Falk Petersen

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad642 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Karl L Insogna und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Endocrinology, Yale School of Medicine, New Haven, CT 06520-8020, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Familial Hypophosphatemic Rickets, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, Ultragenyx.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

In clinical trials, burosumab ameliorates symptoms of pain, fatigue, and stiffness and improves performance on certain muscle function studies in patients with X-linked hypophosphatemia (XLH).

Objective

This work aimed to determine if burosumab increases adenosine triphosphate (ATP) synthesis in skeletal muscle of treatment-naive adults with XLH, and if so, whether that correlates with improved muscle function.

Methods

Ten untreated, symptomatic adults with XLH had ATP synthesis rates measured in the right calf using the 31P magnetic resonance spectroscopy saturation transfer technique. Baseline muscle function tests and symptoms of pain, fatigue, stiffness, and lower-extremity joint pain were quantified. All participants were treated with burosumab, 1 mg/kg every 4 weeks for 12 weeks. ATP synthesis rates and muscle function tests were repeated 2 weeks (“peak”) and 4 weeks (“trough”) after the third dose of burosumab.

Results

All symptoms improved with treatment. Performance on the 6-Minute Walk Test (6MWT) and Sit to Stand (STS) tests also improved. Muscle strength and ATP synthesis rates did not change over the 3 months of the study. When individuals whose performances on the 6MWT and STS test were at or better than the median outcome for those tests were compared to those whose outcomes were below the median, no difference was observed in the rate of change in ATP synthesis. Intracellular muscle concentrations of phosphate were normal.

Conclusion

The improvement in the 6MWT and STS test without changes in muscle strength or ATP synthesis rates suggests that reductions in pain, fatigue, and stiffness may partly explain the improved performance. Intracellular phosphate in skeletal muscle is insulated from hypophosphatemia in XLH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalFamilial Hypophosphatemic RicketsAntibodies, Monoclonal, HumanizedAdultHumansAdenosine TriphosphateMuscle, SkeletalPolyphosphatesPainLegFatigue

Stichwörter der Autor:innen

X-linked hypophosphatemiaburosumabmuscle ATP synthesismuscle function

Substanzen

burosumabAntibodies, MonoclonalAdenosine Triphosphatetriphosphoric acidPolyphosphatesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medicine, Section of Endocrinology, Yale School of Medicine, New Haven, CT 06520-8020, USA.
  • Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT 06510, USA.
  • Rehabilitation Supervisor, Yale New Haven Hospital, New Haven, CT 06510, USA.
  • Department of Pediatrics, Section of Endocrinology, Yale School of Medicine, New Haven, CT 06510, USA.

ORCID-Profile: Karl L Insogna, Stephen Parziale, Yanhong Deng

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • Ultragenyx
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Advanced Translational Science
  • National Institutes of Health

Zitieren

APA

Insogna, K. L., Sullivan, R., Parziale, S., Deng, Y., Carrano, D., Simpson, C., Dufour, S., Carpenter, T., & Petersen, K. F. (2024). Effect of Burosumab on Muscle Function and Strength, and Rates of ATP Synthesis in Skeletal Muscle in Adults With XLH. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad642

Vancouver

Insogna KL, Sullivan R, Parziale S, Deng Y, Carrano D, Simpson C, et al. Effect of Burosumab on Muscle Function and Strength, and Rates of ATP Synthesis in Skeletal Muscle in Adults With XLH. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad642

BibTeX
@article{Insogna2024,
  author = {Insogna, Karl L and Sullivan, Rebecca and Parziale, Stephen and Deng, Yanhong and Carrano, Diana and Simpson, Christine and Dufour, Sylvie and Carpenter, Thomas and Petersen, Kitt Falk},
  title = {Effect of Burosumab on Muscle Function and Strength, and Rates of ATP Synthesis in Skeletal Muscle in Adults With XLH},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad642}
}
Kostenlos starten →